Assenagon Asset Management S.A. Sells 59,497 Shares of Avantor, Inc. (NYSE:AVTR)

Assenagon Asset Management S.A. lessened its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 62.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,177 shares of the company’s stock after selling 59,497 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Avantor were worth $762,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. CCLA Investment Management raised its holdings in Avantor by 4.5% in the 4th quarter. CCLA Investment Management now owns 5,357,703 shares of the company’s stock worth $112,940,000 after purchasing an additional 229,199 shares in the last quarter. Reinhart Partners LLC. raised its stake in Avantor by 3.9% in the fourth quarter. Reinhart Partners LLC. now owns 551,273 shares of the company’s stock worth $11,615,000 after buying an additional 20,540 shares in the last quarter. Salem Investment Counselors Inc. raised its stake in Avantor by 5.2% in the fourth quarter. Salem Investment Counselors Inc. now owns 77,382 shares of the company’s stock worth $1,630,000 after buying an additional 3,825 shares in the last quarter. First Hawaiian Bank boosted its position in Avantor by 28.7% during the 4th quarter. First Hawaiian Bank now owns 109,100 shares of the company’s stock valued at $2,299,000 after acquiring an additional 24,342 shares in the last quarter. Finally, Central Pacific Bank Trust Division grew its holdings in shares of Avantor by 44.1% during the 4th quarter. Central Pacific Bank Trust Division now owns 29,400 shares of the company’s stock worth $619,000 after acquiring an additional 9,000 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Stock Up 0.9 %

Avantor stock opened at $22.07 on Friday. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The stock has a fifty day simple moving average of $21.47 and a two-hundred day simple moving average of $23.38. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The firm has a market cap of $15.02 billion, a price-to-earnings ratio of 47.97, a PEG ratio of 3.53 and a beta of 1.28.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AVTR. UBS Group restated a “neutral” rating and issued a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Robert W. Baird dropped their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Wells Fargo & Company decreased their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Barclays cut their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, Raymond James lowered their target price on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.